Prothena reported 639K in Interest Income for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Acadia Pharmaceuticals ACAD:US 580K 475K
Alnylam Pharmaceuticals ALNY:US 1.9M 887K
Biogen BIIB:US 12.6M 9.7M
BioMarin Pharmaceutical BMRN:US 2.5M 685K
Bluebird Bio BLUE:US 174K 68K
Exelixis EXEL:US 4.76M 2.94M
Intra Cellular Therapies ITCI:US 1.32M 772K
Nektar Therapeutics NKTR:US 1.1M 701K
Prothena PRTA:US 639K 586K
Ultragenyx Pharmaceutical RARE:US 899K 405K
Vertex Pharmaceuticals VRTX:US 10.8M 9.2M
Vital Therapies VTL:US 106K 99K